The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease.
OBJECTIVE
To examine the effect of intravenous iron and erythropoietin-stimulating agents (ESAs) on glycemic control and A1C of patients with diabetes and chronic kidney disease (CKD).


METHODS
This was a prospective study of patients with type 2 diabetes and CKD stage IIIB or IV undergoing intravenous iron (group A) and/or ESA (group B). Full blood profiles were determined over the study period. Glycemic control was monitored using A1C, seven-point daily glucose three times weekly, and continuous glucose monitoring (CGM).


RESULTS
There were 15 patients in both group A and group B. Mean A1C (95% CI) values fell in both groups (7.40% [6.60-8.19] to 6.96% [6.27-7.25], P<0.01, with intravenous iron and 7.31% [6.42-8.54] to 6.63% [6.03-7.36], P=0.013, ESA). There was no change in mean blood glucose in group A (9.55 mmol/l [8.20-10.90] vs. 9.71 mmol/l [8.29-11.13], P=0.07) and in group B (8.72 mmol/l [7.31-10.12] vs. 8.78 mmol/l [7.47-9.99], P=0.61) over the study period. Hemoglobin and hematocrit values significantly increased following both treatments. There was no linear relationship found between the change in A1C values and the rise of hemoglobin following either treatment.


CONCLUSIONS
Both iron and ESA cause a significant fall in A1C values without a change to glycemic control in patients with diabetes and CKD. At the present time, regular capillary glucose measurements and the concurrent use of CGM remain the best alternative measurements of glycemic control in this patient group.
Ng
Jen M
JM
Department of Diabetes and Endocrinology, Hull York Medical School, East Yorkshire, UK. ben.ng@hey.nhs.uk
Cooke
Michelle
M
Bhandari
Sunil
S
Atkin
Stephen L
SL
Kilpatrick
Eric S
ES
D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy* / Q000378:metabolism; D004921:Erythropoietin / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
D001786:Blood Glucose; D004921:Erythropoietin; D006442:Glycated Hemoglobin; D007501:Iron
J Nephrol. 2006 Mar-Apr;19(2):161-7
16736414
Science. 1978 Apr 7;200(4337):21-7
635569
Diabetes Care. 2001 Mar;24(3):495-9
11289474
Med J Aust. 1983 Jan 8;1(1):40-1
6571525
J Am Soc Nephrol. 2007 Mar;18(3):896-903
17267743
Diabetes Care. 2008 Oct;31(10):1945-8
18599529
Diabetes Care. 2010 Apr;33(4):780-5
20067959
Pediatr Int. 1999 Aug;41(4):357-62
10453183
Diabetes Care. 2008 Aug;31(8):1473-8
18540046
Pharmacotherapy. 2009 Apr;29(4):468-72
19323622
Kidney Int Suppl. 1999 Mar;69:S18-21
10084282
J Intern Med. 1990 Feb;227(2):133-6
2299304
Diabetes Care. 2004 Jul;27(7):1761-73
15220264
Diabetes Care. 1998 Feb;21(2):261-4
9539993
Acta Haematol. 2004;112(3):126-8
15345893
J Nephrol. 1998 Mar-Apr;11(2):83-6
9589379
Malays J Pathol. 2008 Dec;30(2):81-6
19291916
N Engl J Med. 2009 Nov 19;361(21):2019-32
19880844
Diabetes Care. 2003 Apr;26(4):1164-9
12663591
Diabetes Care. 2001 May;24(5):909-13
11347753
Lancet. 1980 Jul 19;2(8186):141
6105305
BMJ. 2008 May 24;336(7654):1177-80
18420663
Intern Med. 1998 Oct;37(10):826-30
9840702
Diabet Med. 2008 Feb;25(2):239-40
18215175